아이엠비디엑스

461030KOSDAQ자연과학 및 공학 연구개발업

56.1 / 100

Reference Date: 2026-04-13

Financial Score25.0 / 40

News Sentiment13.1 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 6.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

IMBIX is a global healthcare company leading the way in precision cancer diagnosis and early detection using liquid biopsy and next-generation sequencing (NGS) technologies. Its core business areas include precision diagnosis of advanced cancers, early detection of post-surgical recurrence, and early cancer screening, supported by products like AlphaLiquide®100 and HRR.

Number of Employees

65people

Average Salary

58.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

3.70Industry Average 3.824.0Point

In line with industry avg

ROE

-27.54Industry Average -32.113.5Point

Below industry avg

Debt Ratio

1.67Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2024~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲56.4% (1-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.4% (1-year basis)

ROE Trend

0.0 / 4

Avg ROE -37.3% (improving, 2yr)

Detailed News Sentiment

2 totalPositive 0Neutral 1Negative 0Average Sentiment Score 55

Neutral
[미리보는 이데일리 신문]대세 된 토스, 주거래은행 2위 꿰찼다
코스닥 시장 개편 및 주가 조작 방지 등 자본시장 대개혁에 대한 내용으로, 아이엠비디엑스가 간접적으로 언급되었습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 6,490Won52-week high 12,08052-week low 6,070

1-month return2.0Point

1m -6.89% (slight drop)

Volume trend5.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral정기주주총회결과2026-03-30
Neutral사업보고서 (2025.12)2026-03-20
Neutral감사보고서제출2026-03-20
Neutral[기재정정]주식매수선택권행사2026-03-16